However, because of iron and erythropoietin deficiencies, hyporesponsivenss to erythropoietin, and the hypoxia associated with diabetes [44], the long-term effect of Roxadustat on renal outcomes in patients with diabetes and CKD requires further study. This evidence concerns the gene EPO and chronic kidney disease.